Kevin Monahan

Diagnostic yield of colonoscopy in Lynch Syndrome

We demonstrate a high adenoma burden with distinct phenotypic and gene-specific characteristics in a UK LS population undergoing high quality surveillance

fg.bmj.com/content/earl...

@kevinmonahan.bsky.social & I have an open clinical #PhD position between @stmarkshospital.bsky.social and @icr.ac.uk If you're interested in the biology of pre-cancer in the bowel & want to translate biology for cancer prevention this one could be for you... funded by the brilliant #40tude

We are looking for our new Tom Smith Clinical Research Fellow in #LynchSyndrome and Early Onset ColorectalCancer with @trevorgraham.bsky.social in translational science … thanks to 40tude curing colon cancer for supporting this fellowship - get in touch! @stmarksgenomics.bsky.social @icr.ac.uk

We had the 3rd meeting of the UK EOCRC Research Consortium in beautiful Edinburgh yesterday supported by British Society of Gastroenterology (BSG) and @bowelcanceruk.bsky.social attended by over 50 UK academics - celebrating our first project funding success only 1 year after foundation

James D Watson, co-discoverer of the structure of DNA, dies aged 97 Remembered for breakthrough with Francis Crick, Watson was later ostracised by the scientific establishment over comments on race

James D Watson, co-discoverer of the structure of DNA, dies aged 97

Low Yield of Genetic Testing in Serrated Polyposis Syndrome

journals.lww.com/ctg/fulltext...

And they’re off! 🏁 👟

Elaine Burns🚶‍♀️Vs Danilo Miskovic 🏃

Our colon cancer workshop is on day 2 of ‘Frontiers’ - run or walk with our experts 🌟

(Must watch video below 👇🏻😜)

Sign up to be in with a chance to participate - bit.ly/4ktsvDc

@lnwh.bsky.social
@kevinmonahan.bsky.social

'Everybody's unique in their own way' - Tadej Pogačar plays down greatness after record-breaking fifth consecutive Il Lombardia victory Pogačar dedicates his victory to teammate Rafał Majka

'Everybody's unique in their own way' - Tadej Pogačar
Love this guy - The true #GOAT
www.cyclingnews.com/news/everybo...

DNA mutagenesis driven by transcription factor competition with mismatch repair Competition between transcription factors and mismatch repair machinery drives localized hypermutation at regulatory elements, with implications for cancer and genome evolution.

I'm very pleased to announce the official publication of our lab's paper "DNA mutagenesis driven by transcription factor competition with mismatch repair" in today's issue of Cell! www.cell.com/cell/abstrac...

Can we prevent IBD?

We are delighted to have Prof. Johan Burisch as one of our visiting professors for this years Frontiers congress 🙌🏻

Hear more about Prof. Burisch in the video below ⬇️

Register now - bit.ly/4ktsvDc

@lnwh.bsky.social
@kevinmonahan.bsky.social

Final Call for Abstracts – Deadline Today!⏳

Don't miss your chance to be part of the #InSiGHT2026 Biennial Meeting in #Singapore! 🌏

🗓️ Submission Deadline: 30 September 2025
⏰ Time: Midnight (Singapore Time) / 6pm CET

Submit your abstract now! insight2026.org/abstract-sub...

#Genetics #GIcancer

🚨 Final Call: Abstract submissions for #InSiGHT2026 close TOMORROW – Sept 30!

Join the global conversation on hereditary GI tumours.
Submit now 👉 insight2026.org

Let your research drive progress.

#MedicalResearch #Genetics #GIcancer #AbstractSubmission

Our results support universal and paired somatic and germline multi-gene panels for all EOCRC patients, regardless of MMR status or family history

onlinelibrary.wiley.com/doi/10.1002/...

Low Yield of Genetic Testing in Serrated Polyposis Syndrome - PubMed Genetic testing demonstrated a low diagnostic yield in this SPS cohort, suggesting undefined genetic risk or involvement of other pathophysiological factors. Therefore, genetic testing appears to have...

Genetic testing appears to have limited utility in SPS patients and may primarily identify those with an incidental diagnosis of Lynch syndrome

pubmed.ncbi.nlm.nih.gov/41002021/

Fluctuating DNA methylation tracks cancer evolution at clinical scale Nature - Cancer evolutionary dynamics are quantitatively inferred using a method, EVOFLUx, applied to fluctuating DNA methylation.

Cancer is an evolutionary disease, but does knowing a cancer’s evolutionary past help predict its future? Out today in @nature, we learnt the evolution of 2000 lymphoid cancers and found it was highly correlated with clinical outcomes! (1/7)
rdcu.be/eFrrc

Epigenetic clues from cancer’s past foretell its future An innovative method to trace tumour evolution using patterns of fluctuating DNA modifications could be implemented in the clinic to predict cancer progression.

Lineage tracking using methylation states from longitudinal bulk sampling. Sounds 🆒 and given recent work by @trevorgraham.bsky.social and colleagues, looks real.

Wondering about other applications like 🦠🧫

👉🏻News and views: www.nature.com/articles/d41...
👉🏻Paper
www.nature.com/articles/s41...

🚨 It’s here!
The Scientific Program for InSiGHT 2026 (4–7 March, Singapore 🇸🇬) is now live!
🔗 Check out the full program: insight2026.org/scientific-programme
🧬 Abstracts due 30 Sept – submit yours: insight2026.org/abstract-submission-guidelines

#InSiGHT2026 #HereditaryCancer #GICancerResearch

🚀 Exciting news! We’re launching Young-Insight for InSiGHT members under 40.
Join our first meeting to share ideas & shape the future of our community. Email admin@insight-group.org with subject “Young Insight” to get involved! 🌍✨ #InSiGHT

Comparative insight: hereditary colorectal cancer registries in Iran, Singapore, and South Africa - Familial Cancer This study compares three hereditary colorectal cancer (CRC) registries—the Iranian Hereditary Colorectal Cancer Registry (IHCCR), the Singapore Polyposis Registry (SPR), and the University of Cape To...

The registries’ combined experiences underscore the critical need for integrated, culturally sensitive strategies combining genetic testing, enhanced surveillance, and family-based management to improve outcomes #Polyposis #LynchSyndrome

link.springer.com/article/10.1...

📢 Join us in Singapore for the InSiGHT Biennial Meeting,
4–7 March 2026!

🔹 Abstract Deadline: 20 Sept 2025
🔹 Early Bird: 10 Jan 2026

Link ➡️ insight2026.org

Let’s advance hereditary GI cancer research together!
#InSiGHT2026 #MedicalResearch #GItumours

Come and work with us!
We are seeking a Regional #LynchSyndrome Nursing Lead band 8 for 12 months to provide teaching and training across North London #Genomics apps.trac.jobs/job-advert/7...

Please follow @insight-org.bsky.social on BlueSky and join us for insight2026.org in Singapore, abstract submission now live!

Please follow @insight-org.bsky.social on BlueSky and join us for insight2026.org in Singapore, abstract submission now live!

👋 Welcome to InSiGHT on BlueSky!

We are a global community of researchers, clinicians, and scientists dedicated to advancing the understanding, diagnosis, and management of hereditary GI cancers. Follow us for updates on scientific advances, clinical guidelines, and upcoming events. #InSiGHT

Abstract submission is now open for #Insight2026 ! Deadline 7th September #LynchSyndrome #Polyposis #EOCRC @soniakupfer.bsky.social @swatipatelmd.bsky.social @cgaigc.com @stmarksgenomics.bsky.social @plsdatabase.bsky.social

insight2026.org

Mainstreaming clinicians in colorectal and Gynae teams… think about this study!

St Mark's Frontiers 2025 Register now for our Annual Frontiers in Colorectal and Intestinal Disease Congress, from the 19th–21st November 2025.

Join us 19-21 November for a bigger and better St Mark's Frontiers in Colorectal Disease Meeting, in a beautiful venue in King's Cross London!
Extremely good value, with hybrid options @stmarkshospital.bsky.social

sayso.health/events/front...

St Mark's Frontiers 2025 Register now for our Annual Frontiers in Colorectal and Intestinal Disease Congress, from the 19th–21st November 2025.

Join us 19-21 November for a bigger and better St Mark's Frontiers in Colorectal Disease Meeting, in a beautiful venue in King's Cross London!
Extremely good value, with hybrid options @stmarkshospital.bsky.social

sayso.health/events/front...

Missed opportunities: Germline testing following tumor sequencing - PubMed In this cohort, 60 % of the eligible population by ESMO criteria did not receive GT, most commonly due to lack of referral (over 2/3 of patients). Further, 50 % of patients not referred for GT had mut...

Missed opportunities: Germline testing following tumor sequencing

pubmed.ncbi.nlm.nih.gov/40554180/